Kicking things off at #ASCO23! Excited to connect with the #oncology community as we work towards advancing outcomes for patients worldwide using #AI-powered diagnostics. Curious about our solutions? Stop by Booth #5163 to learn more!
At Quibim, we are driven by an unwavering passion to improve #healthcare outcomes through cutting-edge technology. Our innovative work in medical imaging and #precisionmedicine is transforming the way diagnoses are made and treatments are personalized. We are thrilled to share our latest advancements in the field of medical imaging and precision medicine at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023. With a deep understanding of the power of medical imaging, we have developed advanced tools that enable the anticipation of disease progression and the optimization of therapeutic strategies. Our commitment is to propel Precision Medicine through the application of medical imaging in the field of clinical #oncology and at #ASCO2023, we will be sharing our innovative approach with oncology experts and professionals.
Quibim has been prominently featured in the esteemed Lord O'Shaughnessy review "Commercial clinical trials in the UK" alongside other prestigious institutions. This comprehensive analysis provides valuable insights and recommendations on overcoming key challenges and driving the expansion and growth of the #lifesciences field through commercial clinical trials. Through active collaboration with the NHS, healthcare leaders, and experts in academia and industry, 27 actionable recommendations have been developed. We are honored to be recognized as a trusted resource in this report. Dive into the full article here:
During #LungCancerHopeMonth at Quibim we want to emphasize the critical role of comprehensive biomarker testing for NSCLC patients. Many therapeutic decisions in #lungcancer rely on techniques like next-generation sequencing (NGS) and immunohistochemistry (IHC) to determine tumor mutational status and PD-L1 fraction. With QP-Lung, we are developing an innovative solution that combines existing techniques with baseline CT scan analysis. Our goal is to classify tumor mutational status, predict response to immune checkpoint inhibitors, and assess overall survival. By leveraging advanced #imaging technology and #AI, we aim to enhance #precisionmedicine in lung cancer treatment. Join us in raising awareness as we strive to provide hope and improved outcomes for patients. Learn more about it here https://bit.ly/45xt33T
Introducing the #FLUTE platform, a trailblazing infrastructure set to revolutionize the management of health #data. Leveraging a unique #AI healthcare model, trained on local datasets and transferred between data centers, we can glean insightful information while safeguarding patient privacy. Our mission? To decrease unnecessary biopsies and enhance #patientcare by improving predictions for aggressive #prostatecancer - the second most common cancer worldwide, according to the World Health Organization. With FLUTE, we're rewriting the playbook for #cancercare. Let the game-changing begin! Read everything about it in our blog https://bit.ly/3My6Mu3
Introducing the #FLUTE platform, a trailblazing infrastructure set to revolutionize the management of health #data. Leveraging a unique #AI healthcare model, trained on local datasets and transferred between data centers, we can glean insightful information while safeguarding patient privacy. Our mission? To decrease unnecessary biopsies and enhance #patientcare by improving predictions for aggressive #prostatecancer - the second most common cancer worldwide, according to the World Health Organization. With FLUTE, we're rewriting the playbook for #cancercare. Let the game-changing begin! Read everything about it in our blog https://bit.ly/3My6Mu3
QP-Discovery offers the perfect, all-in-one solution for all your imaging needs: 1. The platform employs advanced image processing and #AI algorithms. 2. Clinical validation has demonstrated its potential to enhance patient outcomes. 3. By partnering with #lifesciences companies, we accelerate pharmaceutical drug development. 4. This accelerated drug development consequently results in more personalized therapies tailored to individual patients. To find out more, click here https://lnkd.in/dUWkdzDA and visit us at #ASCO2023!
As we kick off the #EuropeanWeekAgainstCancer, we're truly privileged to collaborate with organizations and individuals across Europe. Together, we're raising awareness and promoting initiatives that aim to prevent and combat #cancer. Our commitment goes well beyond #EWAC2023. We're dedicated every day to building a future where cancer is preventable and treatable. Through groundbreaking projects like ProCAncer-I project, #ProCanAid, RadioVal, Primage Project, #EUCAIM, The CHAIMELEON Project, Dipcan, and #FLUTE, we're wholeheartedly focused on advancing cancer research, diagnosis, and treatment. Let's keep making a difference!
María José Alarte, Head of Legal at Quibim, recently had the opportunity to participate in a Moot Court Workshop focused on "The Value of Health Data" at the CPDP 2023 event. The Department of Innovation and Digitalization in Law of the Universität Wien organized the workshop. In this fictional court case, participants engaged in stimulating discussions regarding how #data providers should be appropriately rewarded for their significant contributions to the development of medical #AI applications. As this field advances, questions about data providers' contributions become increasingly relevant. It was an excellent opportunity to share valuable insights and expertise from her involvement in the ProCAncer-I project, a research initiative involving #healthdata.
Reflecting on the remarkable journey we've embarked on with the Primage Project, we're thrilled to have played a role in this groundbreaking initiative, set to revolutionize the future of #medicalimaging. Having the privilege of being part of Project PRIMAGE has been truly transformative for us. We are confident that the combined dedication and concerted efforts poured into this venture will redefine the landscape of #pediatriccancer research, profoundly impacting countless lives.
